Overview

With each significant achievement, we have made an enduring impression on our path towards becoming a widely respected organisation. Our goal is to be a valuable collaborator for the pharmaceutical industry as they strive to improve people's lives while prioritising our responsibility to impact the communities we serve positively.

  • 2001

    Land purchase and Construction of Block I & II.

  • 2005

    Started Manufacturing APIs.

  • 2005

    Commissioning of Block I & II.

  • 2010

    Commissioning of Block III.

  • 2014

    1st USFDA Inspection.

  • 2015

    Commissioning of Block IV, USMDF of 10-DAB III and CEP of Digoxin.

  • 2016

    2nd & 3rd USFDA Inspection and 1st EDQM Inspection.

  • 2018

    4th USFDA Inspection and NMPA approval for Digoxin.

  • 2019

    Commissioning of Block V.

  • 2021

    2nd EDQM Inspection (Remote).

  • 2025

    5th USFDA Inspection (0 Observations).

  • 2025

    Successful CFDI (China) Inspection.

  • 2026

    Filled dossier for Cabergoline CEP at EDQM.